Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€316.00

€316.00

0.630%
2.0
0.630%
€290.05

€290.05

 
10.06.26 / Tradegate WKN: 856584 / Symbol: HUM / Name: Humana / Stock / Healthcare Providers & Services / Large Cap /
Latest predictions
04.06.26
8.22%
03.06.26
12.06%
buy
20.05.26
20.61%
20.05.26
20.61%
buy
20.05.26
20.61%
20.05.26
20.61%
buy
Best running prediction
€197.82
12.02.26
109.41%
buy
Your prediction

Humana Inc. Stock

The Humana Inc. stock is trending slightly upwards today, with an increase of €2.00 (0.630%) compared to yesterday's price.
Currently there is a rather positive sentiment for Humana Inc. with 26 Buy predictions and 7 Sell predictions.
On the other hand, the target price of 290 € is below the current price of 316.0 € for Humana Inc., so the potential is actually -8.23%.
Our community identified positive and negative aspects for Humana Inc. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Humana Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.

Humana Inc. (Symbol: HUM) is a leading healthcare and wellness company headquartered in Louisville, Kentucky, specializing in offering a diversified range of health insurance, wellness programs, and managed care plans to individual, group, government, and military customers. With a strong commitment to providing personalized, affordable, and high-quality healthcare solutions, Humana emphasizes on simplifying access and meeting the evolving needs of its vast clientele through leveraging data analytics, technology, and innovation. As a publicly traded entity, Humana’s stock is listed on the New York Stock Exchange, and it forms part of the esteemed S&P 500 index, reflecting its significant impact and presence within the highly competitive healthcare sector.

Pros and Cons of Humana Inc. in the next few years

Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Humana Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Humana Inc. 0.630% 11.268% 35.043% 55.665% 43.898% -33.850% -8.907%
Centene Corp. -1.100% 10.241% 19.200% 16.562% 63.760% -11.875% -3.214%
Cigna Corp. 0.430% 9.717% 4.826% -6.647% 9.296% 3.556% 30.168%
UnitedHealth Group Inc. -0.060% 8.677% 9.553% 32.807% 26.053% -23.134% 7.063%

Comments

Humana (HUM) had its "underweight" rating reaffirmed by Morgan Stanley.
Ratings data for HUM provided by MarketBeat
Show more

Humana (HUM) had its "outperform" rating reaffirmed by Sanford C. Bernstein.
Ratings data for HUM provided by MarketBeat
Show more

Humana (HUM) was downgraded by Wells Fargo & Company from "cautious" to "reduce".
Ratings data for HUM provided by MarketBeat
Show more

News

AdaptHealth Conference: Kaiser Deal Drives Growth, Labor Costs Dent EBITDA
AdaptHealth Conference: Kaiser Deal Drives Growth, Labor Costs Dent EBITDA

AdaptHealth (NASDAQ:AHCO) told investors at a Bank of America event that first-quarter results reflected broad organic growth across its business

Profound Medical Q1 Earnings Call Highlights
Profound Medical Q1 Earnings Call Highlights

Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use

Humana, Nurses on Boards Coalition Announce New Partnership to Mentor Emerging Nurses
Humana, Nurses on Boards Coalition Announce New Partnership to Mentor Emerging Nurses


Humana has announced a new partnership with the national Nurses on Boards Coalition (NOBC) to provide mentors for nursing students.



Humana is providing a gift of $110,000 for first-year funding